

AMENDMENT

The following listing of claims will replace all prior versions and listings of claims in the application.

Listing of the Claims:

1.-37. (Canceled)

38. (Currently Amended) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen comprising ~~[[an]]the~~ amino acid sequence ~~from any~~ of SEQ ID NO: 32 or an antigenic fragment~~[[s]]~~ thereof.

39. (Canceled)

40. (Currently Amended) The pharmaceutical composition of claim 38, wherein the hyperimmune serum-reactive antigen or fragment is further defined as comprising ~~[[an]]the~~ amino acid sequence of: amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 and/or 396-449 of SEQ ID NO: 32.

41. (Currently Amended) The pharmaceutical composition of claim 38, wherein the hyperimmune serum-reactive antigen or fragment comprises at least 6 contiguous amino acids of ~~any of~~ SEQ ID NO: 32.

42. (Currently Amended) The pharmaceutical composition of claim 38, wherein the hyperimmune serum-reactive antigen or fragment comprises at least 8 contiguous amino acids of ~~any of~~ SEQ ID NO: 32.

43. (Currently Amended) The pharmaceutical composition of claim 38, wherein the hyperimmune serum-reactive antigen or fragment comprises at least 10 contiguous amino acids of ~~any of~~ SEQ ID NO: 32.

44-45. (Canceled)

46. (Previously Presented) The pharmaceutical composition of claim 38, wherein the hyperimmune serum-reactive antigen or fragment is directed against *S. epidermidis*.
47. (Previously Presented) The pharmaceutical composition of claim 38, further defined as comprising at least two different hyperimmune serum-reactive antigens and/or fragments.
48. (Previously Presented) The pharmaceutical composition of claim 47, wherein the at least two different hyperimmune serum-reactive antigens and/or fragments are both directed against *S. epidermidis*.
49. (Previously Presented) The pharmaceutical composition of claim 38, further comprising an immunostimulatory substance.
50. (Previously Presented) The pharmaceutical composition of claim 49, wherein the immunostimulatory substance is a polycationic polymer, an immunostimulatory deoxynucleotide (ODN), a peptide containing at least two LysLeuLys motifs, a neuroactive compound, alum, or a Freund's complete or incomplete adjuvant.
51. (Withdrawn) The pharmaceutical composition of claim 50, wherein the polycationic polymer is a polycationic peptide.
52. (Withdrawn) The pharmaceutical composition of claim 50, wherein the neuroactive compound is human growth hormone.
53. (Previously Presented) The pharmaceutical composition of claim 38, further defined as a vaccine.
54. (Previously Presented) The pharmaceutical composition of claim 53, further defined as a vaccine for treatment and/or prevention of *S. epidermidis* infection.
55. (Withdrawn) A method of vaccinating a subject comprising;
obtaining a pharmaceutical composition of claim 38; and
administering the pharmaceutical composition to a subject;
wherein the subject is vaccinated.

56. (Withdrawn) The method of claim 55, wherein the subject is a human.
57. (Withdrawn) The method of claim 55, further defined as a method of treating and/or preventing *S. epidermidis* infection in the subject.
58. (Withdrawn) The method of claim 55, wherein the hyperimmune serum-reactive antigen or fragment is directed against *S. epidermidis*.
59. (Withdrawn) The method of claim 55, wherein the pharmaceutical composition comprises at least two different hyperimmune serum-reactive antigens or fragments thereof.
60. (Withdrawn) The method of claim 59, wherein the at least two different hyperimmune serum-reactive antigens or fragments thereof are both directed against *S. epidermidis*.
61. (New) A pharmaceutical composition comprising an isolated hyperimmune serum-reactive antigen consisting of the amino acid sequence of: amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 or 396-449 of SEQ ID NO: 32.
62. (New) The pharmaceutical composition of claim 61, comprising the isolated hyperimmune serum-reactive antigen consisting of the amino acid sequence of amino acids 396-449 of SEQ ID NO: 32.